Literature DB >> 16113296

Pulmonary interleukin-23 gene delivery increases local T-cell immunity and controls growth of Mycobacterium tuberculosis in the lungs.

Kyle I Happel1, Euan A Lockhart, Carol M Mason, Elizabeth Porretta, Elizabeth Keoshkerian, Anthony R Odden, Steve Nelson, Alistair J Ramsay.   

Abstract

Interleukin-23 (IL-23) is a heterodimeric cytokine that shares IL-12 p40 but contains a unique p19 subunit similar to IL-12 p35. Previous studies indicate a greater importance for intact IL-12/23 p40 expression than IL-12 p35 for immunity against Mycobacterium tuberculosis, suggesting a role for IL-23 in host defense. The effects of IL-23 on the outcome of pulmonary infection with M. tuberculosis have not been described. Here, we show that local delivery of replication-defective adenovirus vectors encoding IL-23 (AdIL-23) greatly stimulated expression of both gamma interferon (IFN-gamma) and IL-17 in lung tissues of otherwise normal mice. When given 72 h prior to infection with M. tuberculosis, AdIL-23 significantly reduced the bacterial burden at 14, 21, and 28 days. Markedly lower levels of lung inflammation were observed at 28 days than in control mice pretreated with control adenovirus (AdNull) or vehicle controls. AdIL-23 pretreatment resulted in increased numbers of CD4(+) CD25(+) activated T cells in lungs and draining lymph nodes compared to control groups and more CD4(+) T cells bearing surface memory markers in lung lymph nodes. IL-23 gene delivery also significantly enhanced host anti-mycobacterial T-cell responses, as shown by elevated levels of IFN-gamma and IL-17 secreted in vitro following restimulation with M. tuberculosis purified protein derivative. Overall, our data show that transient IL-23 gene delivery in the lung is well tolerated, and they provide the initial demonstration that this factor controls mycobacterial growth while augmenting early pulmonary T-cell immunity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16113296      PMCID: PMC1231058          DOI: 10.1128/IAI.73.9.5782-5788.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection.

Authors:  Kyle I Happel; Mingquan Zheng; Erana Young; Lee J Quinton; Euan Lockhart; Alistair J Ramsay; Judd E Shellito; Jill R Schurr; Gregory J Bagby; Steve Nelson; Jay K Kolls
Journal:  J Immunol       Date:  2003-05-01       Impact factor: 5.422

2.  Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment.

Authors:  Atsunobu Takeda; Shinjiro Hamano; Atsushi Yamanaka; Toshikatsu Hanada; Tatsuro Ishibashi; Tak W Mak; Akihiko Yoshimura; Hiroki Yoshida
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

Review 3.  The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses.

Authors:  Giorgio Trinchieri; Stefan Pflanz; Robert A Kastelein
Journal:  Immunity       Date:  2003-11       Impact factor: 31.745

4.  IL-27 signaling compromises control of bacterial growth in mycobacteria-infected mice.

Authors:  John E Pearl; Shabaana A Khader; Alejandra Solache; Leigh Gilmartin; Nico Ghilardi; Fred deSauvage; Andrea M Cooper
Journal:  J Immunol       Date:  2004-12-15       Impact factor: 5.422

5.  Mice lacking bioactive IL-12 can generate protective, antigen-specific cellular responses to mycobacterial infection only if the IL-12 p40 subunit is present.

Authors:  Andrea M Cooper; Andre Kipnis; Joanne Turner; Jeanne Magram; Jessica Ferrante; Ian M Orme
Journal:  J Immunol       Date:  2002-02-01       Impact factor: 5.422

6.  Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17.

Authors:  Sudeepta Aggarwal; Nico Ghilardi; Ming-Hong Xie; Frederic J de Sauvage; Austin L Gurney
Journal:  J Biol Chem       Date:  2002-11-03       Impact factor: 5.157

7.  A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R.

Authors:  Christi Parham; Madaline Chirica; Jacqueline Timans; Elena Vaisberg; Marilyn Travis; Jeanne Cheung; Stefan Pflanz; Rebecca Zhang; Komal P Singh; Felix Vega; Wayne To; Janet Wagner; Anne-Marie O'Farrell; Terrill McClanahan; Sandra Zurawski; Charles Hannum; Daniel Gorman; Donna M Rennick; Robert A Kastelein; Rene de Waal Malefyt; Kevin W Moore
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

8.  Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.

Authors:  Daniel J Cua; Jonathan Sherlock; Yi Chen; Craig A Murphy; Barbara Joyce; Brian Seymour; Linda Lucian; Wayne To; Sylvia Kwan; Tatyana Churakova; Sandra Zurawski; Maria Wiekowski; Sergio A Lira; Daniel Gorman; Robert A Kastelein; Jonathon D Sedgwick
Journal:  Nature       Date:  2003-02-13       Impact factor: 49.962

9.  IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms.

Authors:  Sophie Lucas; Nico Ghilardi; Ji Li; Frédéric J de Sauvage
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

Review 10.  Immunology of tuberculosis and implications in vaccine development.

Authors:  JoAnne L Flynn
Journal:  Tuberculosis (Edinb)       Date:  2004       Impact factor: 3.131

View more
  48 in total

1.  Influence of oral lactoferrin on Mycobacterium tuberculosis induced immunopathology.

Authors:  Kerry J Welsh; Shen-An Hwang; Sydney Boyd; Marian L Kruzel; Robert L Hunter; Jeffrey K Actor
Journal:  Tuberculosis (Edinb)       Date:  2011-12-03       Impact factor: 3.131

2.  Impact of interleukin-17 on macrophage phagocytosis of apoptotic neutrophils and particles.

Authors:  Elin Silverpil; Pernilla Glader; Marit Hansson; Anders Lindén
Journal:  Inflammation       Date:  2011-02       Impact factor: 4.092

Review 3.  Th17 cell dynamics in HIV infection.

Authors:  Nichole R Klatt; Jason M Brenchley
Journal:  Curr Opin HIV AIDS       Date:  2010-03       Impact factor: 4.283

4.  Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice.

Authors:  Anupa Kudva; Erich V Scheller; Keven M Robinson; Chris R Crowe; Sun Mi Choi; Samantha R Slight; Shabaana A Khader; Patricia J Dubin; Richard I Enelow; Jay K Kolls; John F Alcorn
Journal:  J Immunol       Date:  2010-12-22       Impact factor: 5.422

Review 5.  Interleukin-12 and tuberculosis: an old story revisited.

Authors:  Andrea M Cooper; Alejandra Solache; Shabaana A Khader
Journal:  Curr Opin Immunol       Date:  2007-08-16       Impact factor: 7.486

Review 6.  Regulation and function of proinflammatory TH17 cells.

Authors:  Gustavo J Martinez; Roza I Nurieva; Xuexian O Yang; Chen Dong
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

7.  Pure insulin nanoparticle agglomerates for pulmonary delivery.

Authors:  Mark M Bailey; Eric M Gorman; Eric J Munson; Cory Berkland
Journal:  Langmuir       Date:  2008-12-02       Impact factor: 3.882

8.  Modulation of intestinal goblet cell function during infection by an attaching and effacing bacterial pathogen.

Authors:  Kirk S B Bergstrom; Julian A Guttman; Mohammad Rumi; Caixia Ma; Saied Bouzari; Mohammed A Khan; Deanna L Gibson; A Wayne Vogl; Bruce A Vallance
Journal:  Infect Immun       Date:  2007-11-05       Impact factor: 3.441

9.  Interplay between effector Th17 and regulatory T cells.

Authors:  Amit Awasthi; Gopal Murugaiyan; Vijay K Kuchroo
Journal:  J Clin Immunol       Date:  2008-09-23       Impact factor: 8.317

10.  Severe tuberculosis induces unbalanced up-regulation of gene networks and overexpression of IL-22, MIP-1alpha, CCL27, IP-10, CCR4, CCR5, CXCR3, PD1, PDL2, IL-3, IFN-beta, TIM1, and TLR2 but low antigen-specific cellular responses.

Authors:  Liyou Qiu; Dan Huang; Cystal Y Chen; Richard Wang; Ling Shen; Yun Shen; Robert Hunt; James Estep; Barton F Haynes; William R Jacobs; Norman Letvin; George Du; Zheng W Chen
Journal:  J Infect Dis       Date:  2008-11-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.